FDA Approves Tafasitamab-cxix for Relapsed or Refractory Follicular Lymphoma By Ogkologos - August 14, 2025 404 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the inMIND study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR A Combination of Osimertinib Plus Pemetrexed and a Platinum-based Agent Significantly... November 29, 2023 ESMO Immuno-Oncology Virtual Congress 2020 November 30, 2020 Tumour-Infiltrating Clonal Haematopoiesis Increases the Risk of Recurrence or Death Among... May 7, 2025 FDA Grants Regular Approval to Enfortumab Vedotin-ejfv for Locally Advanced or... July 12, 2021 Load more HOT NEWS Tecartus Becomes First CAR T-Cell Therapy Approved for Adults with ALL The Healing Power of Being Outdoors for People With Cancer Treatment Strategy for ecDNA-Driven Tumors Shows Potential Palliative and Supportive Care for Children With Cancer: An Expert Perspective
